Drug Screening Assays, Antitumor
"Drug Screening Assays, Antitumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
Descriptor ID |
D004354
|
MeSH Number(s) |
E01.370.225.500.388 E05.200.500.388 E05.242.417 E05.337.550.200
|
Concept/Terms |
Drug Screening Assays, Antitumor- Drug Screening Assays, Antitumor
- Antitumor Drug Screening Assays
- Cancer Drug Tests
- Cancer Drug Test
- Drug Test, Cancer
- Drug Tests, Cancer
- Test, Cancer Drug
- Tests, Cancer Drug
- Drug Screening Tests, Tumor-Specific
- Drug Screening Tests, Tumor Specific
- Antitumor Drug Screens
- Antitumor Drug Screen
- Drug Screen, Antitumor
- Drug Screens, Antitumor
- Screen, Antitumor Drug
- Screens, Antitumor Drug
- Anti-Cancer Drug Screens
- Anti Cancer Drug Screens
- Anti-Cancer Drug Screen
- Drug Screen, Anti-Cancer
- Drug Screens, Anti-Cancer
- Screen, Anti-Cancer Drug
- Screens, Anti-Cancer Drug
- Anticancer Drug Sensitivity Tests
- Tumor-Specific Drug Screening Tests
- Tumor Specific Drug Screening Tests
|
Below are MeSH descriptors whose meaning is more general than "Drug Screening Assays, Antitumor".
Below are MeSH descriptors whose meaning is more specific than "Drug Screening Assays, Antitumor".
This graph shows the total number of publications written about "Drug Screening Assays, Antitumor" by people in this website by year, and whether "Drug Screening Assays, Antitumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 6 | 6 |
1996 | 1 | 1 | 2 |
1997 | 0 | 3 | 3 |
1998 | 0 | 3 | 3 |
1999 | 0 | 9 | 9 |
2000 | 0 | 5 | 5 |
2001 | 0 | 5 | 5 |
2002 | 0 | 7 | 7 |
2003 | 2 | 10 | 12 |
2004 | 1 | 11 | 12 |
2005 | 2 | 5 | 7 |
2006 | 2 | 20 | 22 |
2007 | 3 | 13 | 16 |
2008 | 2 | 19 | 21 |
2009 | 3 | 18 | 21 |
2010 | 3 | 19 | 22 |
2011 | 2 | 8 | 10 |
2012 | 3 | 13 | 16 |
2013 | 4 | 14 | 18 |
2014 | 2 | 12 | 14 |
2015 | 3 | 13 | 16 |
2016 | 0 | 6 | 6 |
2017 | 2 | 8 | 10 |
2018 | 1 | 13 | 14 |
2019 | 2 | 11 | 13 |
2020 | 2 | 12 | 14 |
2021 | 1 | 10 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Screening Assays, Antitumor" by people in Profiles.
-
Anti-breast cancer action of carbonic anhydrase IX inhibitor 4-[4-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-benzylidene-hydrazinocarbonyl]-benzenesulfonamide (BSM-0004): in?vitro and in?vivo studies. J Enzyme Inhib Med Chem. 2021 Dec; 36(1):954-963.
-
Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor. J Med Chem. 2021 10 28; 64(20):15141-15169.
-
Development of 2'-aminospiro [pyrano[3,2-c]quinoline]-3'-carbonitrile derivatives as non-ATP competitive Src kinase inhibitors that suppress breast cancer cell migration and proliferation. Bioorg Chem. 2021 11; 116:105344.
-
A novel peptidomimetic therapeutic for selective suppression of lung cancer stem cells over non-stem cancer cells. Bioorg Chem. 2021 11; 116:105340.
-
Morphological screening of mesenchymal mammary tumor organoids to identify drugs that reverse epithelial-mesenchymal transition. Nat Commun. 2021 07 12; 12(1):4262.
-
Maximizing the potential of aggressive mouse tumor models in preclinical drug testing. Sci Rep. 2021 06 02; 11(1):11580.
-
Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021 Mar; 165(1):26-33.
-
Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma. Cancer Sci. 2021 Mar; 112(3):1225-1234.
-
Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope. Bioorg Med Chem. 2021 02 15; 32:116013.
-
Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC. Cancer Res. 2021 03 01; 81(5):1398-1412.